1. Home
  2. WSFS vs MLYS Comparison

WSFS vs MLYS Comparison

Compare WSFS & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo WSFS Financial Corporation

WSFS

WSFS Financial Corporation

HOLD

Current Price

$64.64

Market Cap

3.1B

Sector

Finance

ML Signal

HOLD

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$30.98

Market Cap

2.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WSFS
MLYS
Founded
1980
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.1B
2.6B
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
WSFS
MLYS
Price
$64.64
$30.98
Analyst Decision
Buy
Strong Buy
Analyst Count
4
7
Target Price
$68.75
$47.33
AVG Volume (30 Days)
394.4K
1.2M
Earning Date
01-26-2026
02-12-2026
Dividend Yield
1.05%
N/A
EPS Growth
15.38
N/A
EPS
5.09
N/A
Revenue
$1,016,779,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$3.94
N/A
P/E Ratio
$12.72
N/A
Revenue Growth
3.23
N/A
52 Week Low
$42.44
$8.24
52 Week High
$64.75
$47.65

Technical Indicators

Market Signals
Indicator
WSFS
MLYS
Relative Strength Index (RSI) 73.38 35.15
Support Level $57.33 $32.05
Resistance Level $60.35 $33.63
Average True Range (ATR) 1.63 1.62
MACD 0.81 0.05
Stochastic Oscillator 94.28 5.05

Price Performance

Historical Comparison
WSFS
MLYS

About WSFS WSFS Financial Corporation

WSFS Financial Corp is a savings and loan holding company. The company operates in three segments: WSFS Bank provides loans and leases and other financial products to commercial and consumer customers. Cash Connect segment provides ATM vault cash, smart safe, and other cash logistics services; and Wealth Management provides a broad array of planning and advisor services, investment management, personal and institutional trust services, and credit and deposit products to individuals, corporate, and institutional clients. Majority revenue is generated from WSFS Bank segment.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

Share on Social Networks: